Streetbeat News

Stock Prices

RMD

ResMed's stock has been downgraded from Outperform to Sector Perform by RBC Capital, which also lowered its price target from $273 to $202. This has resulted in ResMed shares trading lower.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 6:14 pm

PMVP

PMV Pharmaceuticals Inc announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE trial, showing that PC14586 achieved efficacy in heavily pretreated patients across multiple tumor types and was well tolerated. The overall response rate was 38% at the Recommended Phase 2 Dose of 2000 mg daily. A recommended phase 2 dose of 2000 mg once daily was selected based on overall safety, pharmacokinetics, and efficacy. PMV plans to initiate a registrational Phase 2 trial in early 2024. PMVP shares are down 39.20% at $2.89.

Portfolio Pulse from Vandana Singh

October 12, 2023 | 6:13 pm

EDSA

Edesa Biotech Inc (NASDAQ:EDSA) has secured a commitment of up to C$23 million from the Government of Canada for a Phase 3 clinical study of the company's first-in-class therapeutic candidate, EB05. The drug, which reduced mortality by 84% among critically ill patients with ARDS in a Phase 2 study, is designed to modulate the body's immune response to infectious diseases. The funding will be used for study expenses and scale-up of commercial drug product if successful. EDSA shares are up 81.50% at $4.90.

Portfolio Pulse from Vandana Singh

October 12, 2023 | 6:10 pm

RVLP

RVL Pharmaceuticals plc's (NASDAQ:RVLP) operating subsidiaries are filing for bankruptcy in a prepackaged deal with lender Athyrium Capital. The reorganization will allow the RVL subsidiaries to reduce debt, streamline operations, and position themselves under new ownership. RVL's public equity is expected to be canceled upon completion of its wind-down, anticipated during 2024, likely resulting in no recovery to public shareholders. RVLP shares are down 65.2% at $0.05 on the last check Thursday.

Portfolio Pulse from Vandana Singh

October 12, 2023 | 6:08 pm

ABT

A significant amount of unusual options activity has been detected for Abbott Laboratories (NYSE:ABT), with an equal split between bullish and bearish expectations. The trades include 5 puts totaling $353,531 and 5 calls totaling $347,449. Whales have been targeting a price range from $75.0 to $95.0 for Abbott Laboratories over the last 3 months. The price of ABT is currently up 0.18% at $92.3.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 6:03 pm

BSX

Unusual options activity has been observed for Boston Scientific (NYSE:BSX), with a bearish stance taken by a large investor. The overall sentiment of these big-money traders is split between 45% bullish and 54% bearish. The price of BSX is down -3.55% at $49.1. Barclays, Needham, Baird, Mizuho, and Citigroup have maintained their ratings on Boston Scientific with price targets ranging from $60 to $63.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 6:03 pm

MS

A significant amount of unusual options activity has been detected for Morgan Stanley (NYSE:MS), with a bearish stance being taken by a majority of investors. The trades have targeted a price range from $77.5 to $85.0 for Morgan Stanley over the last 3 months. The current price of MS is $78.98, up 0.1%. Analysts from JP Morgan and Oppenheimer maintain positive ratings on Morgan Stanley, while RBC Capital and UBS have downgraded their ratings.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 6:03 pm

BAH

Analysts have provided various ratings for Booz Allen Hamilton (NYSE:BAH) within the last quarter, with 3 bullish, 2 somewhat bullish, and 2 indifferent. The average 12-month price target for BAH has increased by 8.7% from the previous average, now standing at $130.29.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 6:01 pm

CASY

Casey's General Stores (NASDAQ:CASY) has received various analyst ratings in the last quarter, with 3 bullish, 6 somewhat bullish, and 3 indifferent. The average 12-month price target for the company has increased by 8.04% from the previous average, now standing at $277.67.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 6:01 pm

CFLT

Over the last quarter, Confluent (NASDAQ:CFLT) has received 4 bullish, 2 somewhat bullish, and 2 indifferent ratings from analysts. The average 12-month price target for the company has increased by 23.88% from $33.00 to $40.88, with a high of $45.00 and a low of $36.00.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 6:01 pm